WO2003068731A1 - Beta-aminoketonen zur behandlung von schmerz - Google Patents
Beta-aminoketonen zur behandlung von schmerz Download PDFInfo
- Publication number
- WO2003068731A1 WO2003068731A1 PCT/EP2003/001319 EP0301319W WO03068731A1 WO 2003068731 A1 WO2003068731 A1 WO 2003068731A1 EP 0301319 W EP0301319 W EP 0301319W WO 03068731 A1 WO03068731 A1 WO 03068731A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tert
- unsubstituted
- beta
- kept
- alkyl
- Prior art date
Links
- 0 C[C@](C(c1ccc(C)cc1)NC1=*C(C)(C)O1)C(CCc(cc1)ccc1Br)=O Chemical compound C[C@](C(c1ccc(C)cc1)NC1=*C(C)(C)O1)C(CCc(cc1)ccc1Br)=O 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Definitions
- the invention relates to beta-aminoketones, a process for their - in particular stereoselective - production, medicaments containing beta-aminoketones according to the invention and the use of beta-aminoketones according to the invention for the production of medicaments for the treatment of pain.
- a well-known therapeutic agent for the treatment of severe pain is tramadol hydrochloride - (1 RS, 2RS) -2 - [(dimethylamino) methyl] -1 - (3-methoxyphenyl) cyclohexanol, hydrochloride.
- Aminomethyl-aryl-cyclohexanol derivatives such as tramadol ((1RS, 2RS) -2-dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclo-hexanol, hydrochloride) can have an analgesic effect, but also hydroxylated tramadol derivatives as described for example in EP 753506 A1, or they can be used as intermediates for the preparation of analgesically active substances can be used (such as 4- or 5-substituted tramadol analogs, which are described in EP 753 506 A1 or EP 780 369 A1).
- Tramadol in particular, occupies a special position among the centrally active analgesics in that this active ingredient produces strong pain relief without the side effects known for opioids (J. Pharmacol. Exptl. Ther. 267, 331 (1993)), both the enantiomers of tramadol and the enantiomers of tramadol metabolites are involved in the analgesic effect (J. Pharmacol. Exp. Ther. 260, 275 (1992)).
- the invention therefore relates to beta-aminoketones according to general formula I.
- Ri is selected from
- R 2 is selected from
- R 3 is selected from
- C ⁇ _ 4 alkyl substituted or unsubstituted, branched or unbranched, saturated or unsaturated; or benzyl, mono- or polysubstituted or unsubstituted;
- beta-amino ketones according to the invention are in a stereoselectively pure form, in particular in an anti-conformation according to formula Ia or a syn conformation according to formula Ib
- the invention also relates to beta-aminoketones according to the general formula XX
- Ri is selected from
- C ⁇ -4 alkyl substituted or unsubstituted, branched or unbranched, saturated or unsaturated; or phenyl, mono- or polysubstituted or unsubstituted;
- R 2 is selected from
- R is selected from H; or C- ⁇ _ 2 alkyl, substituted or unsubstituted, saturated or unsaturated;
- beta-amino ketones according to the invention are in a stereoselectively pure form, in particular in an anti-conformation according to formula XXa or a syn-conformation according to formula XXb
- the compounds shown are effective analgesics.
- alkyl or cycloalkyl radicals are understood to mean saturated and unsaturated (but not aromatic), branched, unbranched and cyclic hydrocarbons, which can be unsubstituted or mono- or polysubstituted.
- C 3-4 -cycloalkyl stands for C3- or C4-cycloalkyl, C 3-5 -cycloalkyl for C3-, C4- or C5-cycloalkyl, C 3-6 -cycloalkyl for C3-, C4-, C5- or C6 -Cycloalkyl, C 3-7 -cycloalkyl for C3-, C4-, C5-, C6- or C7-cycloalkyl, C 3-8 -cycloalkyl for C3-, C4-, C5-, C6-, C7- or C8- Cycloalkyl, C 4-5 cycloalkyl for C4 or C5 cycloalkyl, C -6 cycloalkyl for C4, C5 or C6 cycloalkyl, C -7 cycloalkyl for C4, C5, C6 or C7 cycloalkyl , C 5-6 cycloalkyl for C5 or C6 cyclo
- cycloalkyl also includes saturated cycloalkyls in which one or two carbon atoms have been replaced by a hetero atom, S, N or O.
- cycloalkyl also includes, in particular, one or more, preferably mono-, unsaturated cycloalkyls without a hetero atom in the ring, as long as the cycloalkyl is not an aromatic system.
- alkyl or cycloalkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propynyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl, Pentyl, 1, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, but also Adamantyl, CHF2, CF3 or CH2OH as well
- substituents here are F, Cl and OH.
- the hydrogen radical can also be substituted by OC-] -3- alkyl or C ⁇ _ 3 -alkyl (each one or more times substituted or unsubstituted), in particular methyl, ethyl, n-propyl, i-propyl, CF 3 , methoxy or Ethoxy, be replaced.
- (CH 2 ) 3 -6 is -CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 -CH2-CH 2 -, -CH 2 - CH 2 -CH 2 -CH 2 -CH 2 - and CH2-CH 2 -CH2-CH 2 -CH2-CH 2 - to understand, under (CH 2 ) 1-4 is -CH 2 -, -CH2-CH2-, -CH2-CH2-CH2- and -CH 2 -CH 2 -CH 2 -CH 2 - to understand, etc.
- An aryl radical is understood to mean ring systems with at least one aromatic ring but without heteroatoms in even one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl or anthracenyl radicals, which can be unsubstituted or mono- or polysubstituted.
- a heteroaryl radical is understood to mean heterocyclic ring systems with at least one unsaturated ring which contain one or more heteroatoms from the group consisting of nitrogen, oxygen and / or sulfur and can also be mono- or polysubstituted. Examples include from the group of heteroaryls furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo [1, 2.5] thiadiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole , Indole and quinazoline listed.
- substituted - if not expressly defined otherwise means the substitution of aryl or heteroaryl with R 23 , OR 23, a halogen, preferably F and / or Cl, a CF3, a CN, a NO2, one NR 4 R 2 5, e j nem
- the radical R " is H, a C ⁇ - j Q-alkyl, preferably a
- Aryl or heteroaryl radical where these aryl and heteroaryl radicals themselves may not be substituted with aryl or heteroaryl radicals,
- radicals R 24 and R 2 ⁇ , identical or different, for H, a C-
- radicals R 24 and R 25 together denote CH 2 CH 2 CH2 ⁇ CH 2
- the radical R 26 represents H, a C j _ ⁇ o-alkyl, preferably a an aryl or heteroaryl radical or a C j on _3-alkyl, saturated or unsaturated, or a C j _3-alkylene group bound aryl or
- Heteroaryl radical where these aryl and heteroaryl radicals themselves may not be substituted with aryl or heteroaryl radicals.
- the term salt is to be understood to mean any form of the active substance according to the invention in which it takes on an ionic form or is charged and is coupled to a counterion (a cation or anion) or is in solution.
- This also includes complexes of the active ingredient with other molecules and ions, in particular complexes that are complexed via ionic interactions.
- physiologically compatible salt with cations or bases means salts of at least one of the compounds according to the invention - usually one (deprotonated) acid - as an anion with at least one, preferably inorganic, cation, which is physiologically - in particular when used in humans and / or mammal - are compatible.
- Particularly preferred are the salts of the alkali and alkaline earth metals but also with NH 4 + , but especially (mono-) or (di-) sodium, (mono-) or (di-) potassium, magnesium or calcium salts.
- physiologically compatible salt with anions or acids is understood to mean salts of at least one of the compounds according to the invention - mostly protonated, for example on nitrogen - as a cation with at least one anion which is physiologically - in particular when used in humans and / or Mammal - are compatible.
- this is understood in particular to mean the salt formed with a physiologically compatible acid, namely salts of the respective active ingredient with inorganic or organic acids which are physiologically compatible, in particular when used in humans and / or mammals.
- physiologically acceptable salts of certain acids are salts of: hydrochloric acid, Hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid, 1,1-dioxo-1,2-dihydrol ⁇ 6 -benzo [d] isothiazol-3-one ( saccharin)
- Nicotinic acid 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethylbenzoic acid, ⁇ -lipoic acid, acetylglycine, acetylsalicylic acid, hippuric acid and / or aspartic acid.
- the hydrochloride salt is particularly preferred.
- Ri is selected from
- R 5 selected from OC- ⁇ - alkyl or C ⁇ -4 alkyl (each substituted or unsubstituted, branched or unbranched, saturated or unsaturated) or halogen, phenyl substituted in the para position.
- R 4 is selected from H or CH 3 , in particular H.
- Another object of the invention are beta-aminoketones according to general formula II
- R 2 is selected from
- R 3 is selected from
- -CC alkyl substituted or unsubstituted, branched or unbranched, saturated or unsaturated; or benzyl, mono- or polysubstituted or unsubstituted;
- R 5 is selected from
- beta-amino ketones according to the invention are in a stereoselectively pure form, in particular in an anti-conformation according to formula IIIa or a syn-conformation according to
- Another object of the invention are beta-aminoketones according to the general formula XXI
- R 2 is selected from
- R 5 is selected from
- beta-amino ketones according to the invention are in a stereoselectively pure form, in particular in an anti-conformation according to formula XXIa or a syn-conformation according to formula XXI b
- R 5 is selected from
- R 2 is selected from
- Aryl or heteroaryl each mono- or polysubstituted or unsubstituted;
- phenyl substituted with R 6 in the para position selected from R 6 OC- alkyl, C1-4 alkyl or halogen; in particular
- R 2 is selected from
- beta-aminoketones according to the invention if, if they have R 3 ,
- R 3 is selected from C 2 H 5 , CH 3 , i-propyl, tert. butyl; or benzyl, mono- or polysubstituted or unsubstituted;
- beta-amino ketones selected from:
- the invention further provides a process for the preparation of beta-aminoketones of the general formula I according to reaction scheme III according to the invention:
- TMSCI is used and the reaction takes place in the presence of a base
- step b the temperature is kept at ⁇ 0 ° C, a polar or non-polar organic solvent is used, and the reaction takes place in the presence of a Lewis acid;
- step c the temperature is kept at ⁇ 0 ° C, a non-polar organic solvent is used, TBAF or HF are used.
- Another object of the invention is a process for the preparation of beta-amino ketones of the general formula II according to the reaction scheme purple:
- TMSCI is used and the reaction takes place in the presence of a base
- step b the temperature is kept at ⁇ 0 ° C, a polar or non-polar organic solvent is used, and the reaction takes place in the presence of a Lewis acid;
- step c the temperature is kept at ⁇ 0 ° C, a non-polar organic solvent is used, TBAF or HF are used.
- a non-polar organic solvent is used, TBAF or HF are used.
- step a the temperature is kept at ⁇ -78 ° C. and / or THF is used as the non-polar organic solvent and / or LDA is used as the base; and
- step b the temperature is kept at ⁇ -78 ° C., and / or CH 2 Cl 2 is used as the polar organic solvent, and / or TiCl 4 or SnCl 4 , preferably TiCl, is used as Lewis acid; and / or particularly preferably additionally KH is used.
- step c the temperature is kept at ⁇ -78 ° C, and / or THF is used as the non-polar organic solvent, and / or is used to adjust a pH ⁇ 7 NH F and TBAF or HF are used.
- Another object of the invention is a process for the stereoselective production of anti-beta aminoketones of the general formula IIIa according to the reaction scheme IIIb according to the invention:
- TMSCI and HMPA are used and the reaction takes place in the presence of a base
- step b the temperature is kept at ⁇ -70 ° C., a polar organic solvent is used, and the reaction takes place in the presence of a Lewis acid;
- step c the temperature is kept at ⁇ -70 ° C, a non-polar organic solvent is used, TBAF or HF are used and the reaction takes place at a pH ⁇ 7.
- a non-polar organic solvent is used, TBAF or HF are used and the reaction takes place at a pH ⁇ 7.
- step a the temperature is kept at ⁇ -78 ° C. and / or THF is used as the non-polar organic solvent and / or LDA is used as the base; and
- step b the temperature is kept at ⁇ -78 ° C., and / or CH 2 Cl 2 is used as the polar organic solvent, and / or TiCl 4 or SnCl 4 , preferably TiCl, is used as Lewis acid; and / or particularly preferably additionally KH is used.
- step c the temperature is kept at ⁇ -78 ° C, and / or THF is used as the non-polar organic solvent, and / or is used to adjust a pH ⁇ 7 NH 4 F and TBAF or HF are used.
- the invention further provides a process for the preparation of beta-aminoketones of the general formula I according to reaction scheme IV according to the invention:
- step c the temperature is kept at ⁇ 0 ° C, a non-polar organic solvent is used, TBAF or HF are used.
- the invention further relates to a process for the stereoselective production of syn-beta-amino ketones of the general formula Ib according to the reaction scheme IVa according to the invention:
- HMPA is used and the reaction takes place in the presence of a base
- step c the temperature is kept at ⁇ -70 ° C, a non-polar organic solvent is used, TBAF or HF are used and the reaction takes place at a pH ⁇ 7.
- Another object of the invention is a process for the preparation of beta-aminoketones of the general formula II according to the reaction scheme IVb:
- step c the temperature is kept at ⁇ 0 ° C, a non-polar organic solvent is used, TBAF or HF are used.
- Another object of the invention is a process for the stereoselective preparation of syn-beta-amino ketones of the general formula II b according to the reaction scheme IVc:
- HMPA HMPA is used, and the reaction takes place in the presence of a base
- step c the temperature is kept at ⁇ -70 ° C, a non-polar organic solvent is used, TBAF or HF are used and the reaction takes place at a pH ⁇ 7.
- a non-polar organic solvent is used, TBAF or HF are used and the reaction takes place at a pH ⁇ 7.
- step d the temperature is kept at ⁇ -78 ° C., and / or THF is used as the non-polar organic solvent, HMPA is used and / or a lithium base, preferably LDA, is used as the base.
- step c the temperature is kept at ⁇ -78 ° C, and / or THF is used as the non-polar organic solvent, and / or is used to adjust a pH ⁇ 7 NH F and TBAF or HF are used.
- Another subject is a process for the preparation of the compounds according to the invention with a free NH 2 group, in which, after completion of one of the processes III, lilac, IIIb, IV, IVa, IVb or IVc, in which R 3 is tert. Butyl corresponds, the compounds prepared are reacted with trifluoroacetic acid and the solvent is removed, so that a compound according to the invention with a free NH 2 group is formed in the form of the triflate.
- Another subject is another process for the preparation of the compounds according to the invention with a free NH 2 group, in which, after completion of one of the processes III, purple, IIIb, IV, IVa, IVb or IVc, in which R 3 is not tert. Butyl corresponds, the compounds prepared are reacted with HCl and the solvent is removed.
- the substances according to the invention are toxicologically harmless, so that they are suitable as active pharmaceutical ingredients in pharmaceuticals.
- the invention therefore furthermore relates to medicaments comprising at least one beta-aminoketone according to the invention and, if appropriate, further active ingredients, auxiliaries and / or additives.
- the medicaments according to the invention optionally contain suitable additives and / or auxiliaries, including carrier materials, fillers, solvents, diluents, dyes and / or binders, and can be used as liquid dosage forms in the form of injection solutions, drops or juices semi-solid dosage forms in the form of granules, tablets, pellets, patches, capsules, plasters or aerosols can be administered.
- suitable additives and / or auxiliaries including carrier materials, fillers, solvents, diluents, dyes and / or binders
- the amounts to be used depend on whether the medicinal product is orally, orally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example on the skin, mucous membranes or in the eyes to be applied.
- Preparations in the form of tablets, dragees, capsules, granules, drops, juices and syrups are suitable for oral administration, and solutions, suspensions, easily reconstitutable dry preparations and sprays are suitable for parenteral, topical and inhalative administration.
- Compounds according to the invention in a depot, in dissolved form or in a plaster, optionally with the addition of agents which promote skin penetration, are suitable percutaneous application preparations. Formulations which can be used orally or percutaneously can release the compounds according to the invention with a delay. In principle, other active substances known to the person skilled in the art can be added to the medicaments according to the invention.
- the amount of active ingredient to be administered to the patient varies depending on the weight of the patient, the type of application, the indication and the severity of the disease. Usually 0.005 to 1000 mg / kg, preferably 0.05 to 5 mg / kg of at least one compound according to the invention.
- Another object of the invention is the use of a beta-amino ketone according to the invention for the manufacture of a medicament for the treatment of pain, anxiety, depression or epilepsy, in particular pain.
- step b (scheme IIIb, method B) (AAV3)
- the purification was carried out by crystallization from n-pentane, diethyl ether or dichloromethane at -20 ° C.
- the ⁇ -aminoketones Ila, Ib and IIb were obtained as colorless solids.
- Mass spectrum (El, 70 eV): m / z (rl%) 446 (1, M + ), 391 (7), 389 (7), 211 (4), 206 (27), 171 (10), 169 (7), 151 (9), 150 (100), 147 (4), 134 (4), 132 (5), 118 (14), 117 (7), 107 (7), 106 (81), 104 (9), 79 (5), 77 (5), 57 (5).
- Mass spectrum (El, 70 eV): m / z (rl%) 423 (5.0, M + ), 368 (6), 367 (22), 306 (5), 218 (6), 206 (15), 189 (6), 161 (5), 160 (10), 151 (9), 150 (100), 147 (18), 145 (8), 134 (5), 133 (13), 132 (8), 118 (9), 117 (8), 107 (7), 106 (84), 91 (5), 57 (43).
- Mass spectrum (El, 70 eV): m / z (rl%) 423 (25, M + ), 380 (5), 288 (10), 241 (6), 236 (11), 217 (5), 206 (13), 192 (6), 189 (10), 172 (12), 163 (5), 162 (25), 161 (8), 154 (5), 148 (8), 147 (17), 117 (6), 116 (24), 92 (8), 91 (100), 72 (27), 57 (14).
- Mass spectrum (El, 70 eV): m / z (rl%) 446 (1, M + ), 390 (23), 389 (21), 211 (4), 207 (4), 206 (34), 184 ( 4), 182 (4), 170 (13), 169 (13), 151 (9), 150 (100), 147 (4), 134 (4), 132 (7), 118 (15), 117 ( 9), 107 (6), 106 (70), 104 (9), 77 (5), 57 (59).
- Mass spectrum (El, 70 eV): m / z (rl%) 503 (1, M + ), 447 (5), 445 (5), 402 (4), 400 (4), 263 (5), 262 (25), 207 (15), 206 (100), 174 (4), 171 (6), 169 (6), 163 (6), 162 (37), 159 (4), 147 (5), 146 (4), 97 (4), 85 (4), 71 (6), 69 (4), 57 (48), 55 (7).
- Mass spectrum (El, 70 eV): m / z (rl%) 436 (2, M + ), 382 (6), 381 (36), 380 (7), 379 (35), 337 (5), 335 (6), 321 (5), 211 (5), 185 (6), 171 (18), 168 (22), 166 (10), 149 (5), 141 (7), 140 (91), 124 (19), 122 (8), 108 (21), 107 (6), 104 (9), 97 (9), 96 (100), 90 (5), 79 (5), 77 (5), 71 (5), 69 (7), 57 (74).
- cleavage methods are the following methods known from the literature with the reagents: trifluoroacetic acid (CF 3 COOH) in CH 2 CI 2 ; Trifluoroacetic acid (CF 3 COOH) and thiophenol (PhSH); HCI in methanol or ethyl acetate; aqueous HCl in THF or CH 2 CI 2 ; Trimethylsilyl iodide (Me 3 Sil) in CHCI3 or CH3CN; Aluminum chloride (AICI3), methylphenyl ether (PhOMe), CH 2 CI 2 , CH 3 NO 2 ; bromocatecholborane; Trimethylsilyl chloride (Me 3 SiCI), methylphenyl ether, CH 2 CI 2 ; Trifluoromethanesulfonic acid (CF 3 SO 3 H); Trimethylsilyl triflate (TMSOTf), PhSMe, trifluoroacetic acid (CF 3 COOH); 10% or conc.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003208829A AU2003208829A1 (en) | 2002-02-14 | 2003-02-11 | Beta-amino ketones for the treatment of pain |
EP03706475A EP1474384A1 (de) | 2002-02-14 | 2003-02-11 | Beta-aminoketonen zur behandlung von schmerz |
US10/917,522 US20050096361A1 (en) | 2002-02-14 | 2004-08-13 | Beta-amino ketones for the treatment of pain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10206403.2 | 2002-02-14 | ||
DE10206403A DE10206403A1 (de) | 2002-02-14 | 2002-02-14 | Synthese von Beta-Aminoketonen |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/917,522 Continuation US20050096361A1 (en) | 2002-02-14 | 2004-08-13 | Beta-amino ketones for the treatment of pain |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003068731A1 true WO2003068731A1 (de) | 2003-08-21 |
Family
ID=27635011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/001319 WO2003068731A1 (de) | 2002-02-14 | 2003-02-11 | Beta-aminoketonen zur behandlung von schmerz |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1474384A1 (de) |
AU (1) | AU2003208829A1 (de) |
DE (1) | DE10206403A1 (de) |
WO (1) | WO2003068731A1 (de) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0753506A1 (de) * | 1995-07-11 | 1997-01-15 | Grünenthal GmbH | 6-dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe |
EP0780369A1 (de) * | 1995-12-20 | 1997-06-25 | Grünenthal GmbH | 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-olverbindungen als pharmazeutische Wirkstoffe |
EP0864559A1 (de) * | 1997-03-14 | 1998-09-16 | Grünenthal GmbH | Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen |
-
2002
- 2002-02-14 DE DE10206403A patent/DE10206403A1/de not_active Withdrawn
-
2003
- 2003-02-11 WO PCT/EP2003/001319 patent/WO2003068731A1/de not_active Application Discontinuation
- 2003-02-11 EP EP03706475A patent/EP1474384A1/de not_active Withdrawn
- 2003-02-11 AU AU2003208829A patent/AU2003208829A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0753506A1 (de) * | 1995-07-11 | 1997-01-15 | Grünenthal GmbH | 6-dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe |
EP0780369A1 (de) * | 1995-12-20 | 1997-06-25 | Grünenthal GmbH | 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-olverbindungen als pharmazeutische Wirkstoffe |
EP0864559A1 (de) * | 1997-03-14 | 1998-09-16 | Grünenthal GmbH | Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen |
Non-Patent Citations (2)
Title |
---|
ENDERS D ET AL.: "Alpha-Silyl Controlled Asymmetric Mannich Reactions of Acyclic Ketones with Imines", SYNLETT, no. 5, 2000, pages 644 - 646, XP009010583 * |
ENDERS D ET AL.: "Asymmetric Mannich Reactions with alpha-Silylated Trimethylsilyl Enol Ethers and N-Alkoxycarbonyl Imines", SYNLETT, no. 3, 4 March 2002 (2002-03-04), pages 471 - 473, XP009010578 * |
Also Published As
Publication number | Publication date |
---|---|
DE10206403A1 (de) | 2003-08-28 |
AU2003208829A1 (en) | 2003-09-04 |
EP1474384A1 (de) | 2004-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1633697B1 (de) | Verfahren zur herstellung substituierter 3-aryl-butyl-aminverbindungen | |
EP2518052B1 (de) | Substituierte 4-Aminocyclohexan-Derivate | |
DE19525137A1 (de) | 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen als pharmazeutische Wirkstoffe | |
EP2257526B1 (de) | Spiro(5.5)undecan derivate | |
EP1368299B1 (de) | Substituierte c-cyclohexylmethylamin-derivate | |
WO1998015526A1 (en) | O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same | |
CA2421990C (en) | .beta.-thioamino acids | |
EP1322592B1 (de) | Substituierte 1-aminobutan-3-ol-derivate | |
EP1406858B1 (de) | Substituierte 4-aminocyclohexanole | |
EP1549647A1 (de) | Substituierte c-imidazo[1,2-a]pyridin-3-yl-methylamine | |
EP1487778B1 (de) | Substituierte 4-aminocyclohexanole | |
EP1406859B1 (de) | Substituierte 4-aminocyclohexanolderivate | |
WO2003068731A1 (de) | Beta-aminoketonen zur behandlung von schmerz | |
EP1549650A1 (de) | Substituierte c-imidazo[1,2-a]lpyridin-3yl-methylamine | |
EP1406623B1 (de) | Substituierte 1-phenethylpiperidinverbindungen, die unter anderem als analgetika verwendung finden | |
EP1322590B1 (de) | Substituierte 5-amino-1-penten-3-ol-derivate | |
DE60031299T2 (de) | Verfahren zur industriellen Herstellung von (Aminomethyl)trifluormethlcarbinol-Derivaten | |
WO2003068204A1 (de) | Synthese von substituierten sulfonylaminen | |
WO2003068734A1 (de) | Carbamidestern zur behandlung von schmerz | |
US20050096361A1 (en) | Beta-amino ketones for the treatment of pain | |
DE10135637A1 (de) | Substituierte 4-Aminocyclohexanolderivate | |
DE10135635A1 (de) | Analgetische substituierte 4-Aminocyclohexanolderivate | |
WO1997016417A1 (en) | Novel sulfamate compound containing carbamoyl group |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003706475 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10917522 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003706475 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003706475 Country of ref document: EP |